In contrast, knockdown of IGF2BP2 in P-MSCs resulted in a diminution of its promoting effect on gastric cancer cell proliferation (Fig. 4E, F), migration (Fig. 4G), and drug resistance (Fig. 4H, I). This evidence concerns the gene IGF2BP2 and gastric cancer.